Gossamer Bio to Present at Three September Healthcare Conferences

Gossamer Bio to Present at Upcoming Investor Conferences

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

08/29/2025 - 07:31 AM

SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following investor conferences in September.

Cantor Global Healthcare Conference
听
Date / Time:	September 3rd, at 9:10 AM ET
Format:	Fireside Chat & 1虫1鈥檚
Location:	New York, NY
Webcast Link:

Wells Fargo Healthcare Conference
听
Date / Time:	September 4th
Format:	1虫1鈥檚
Location:	Boston, MA

H.C. Wainwright 27th Annual Global Healthcare
听
Date / Time:	September 9th, at 8:00 AM ET
Format:	Fireside Chat & 1虫1鈥檚
Location:	New York, NY

About Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.